therefore, the small sample size, inconsistent treatment protocols, and incomplete follow-up restricted the results of our study
Over up to seven years of follow-up, those treated with semaglutide or tirzepatide had a 37% lower risk of developing dementia (hazard ratio [HR] 0.63, 95% CI 0.500.81), a 19% lower risk of stroke (HR 0.81, 95% CI 0.700.93), and a 30% lower risk of all-cause mortality (HR 0.70, 95% CI 0.630.78), compared to those on other antidiabetic drugs
Docetaxel is the first-line chemotherapeutic agent for mCRPC
External resources PubMed: AOD 9604 lipolytic activity study - Research on AOD 9604 mechanism of action in adipose tissue New England Journal of Medicine: STEP 1 Trial - Landmark semaglutide weight loss trial with 1,961 participants FDA: Semaglutide safety information - Official FDA information on approved semaglutide formulations WADA Prohibited List - Current prohibited substances list including growth hormone fragments ClinicalTrials.gov: Semaglutide trials - Registry of ongoing and completed semaglutide clinical trials Choosing between AOD 9604 and semaglutide is ultimately a decision that depends on your individual circumstances, health status, and weight loss goals
Here are the results from each clinical trial
Atropine: Clinical Pharmacology and Emergency Application
